IL6 and colorectal carcinoma: Furthermore, as part of the interactions among inflammatory cytokines, TNF, as such a mediator, can induce IL-6 expression in colorectal carcinomas, inducing therapeutic benefits in CRC clinical trials through IL-6 inhibition and anti-TNF therapies [47,48,49].